IRIS
NOZZA, SILVIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 326
NA - Nord America 260
AS - Asia 144
Totale 730
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 260
SE - Svezia 159
RU - Federazione Russa 83
SG - Singapore 83
CN - Cina 52
IT - Italia 51
FI - Finlandia 21
DE - Germania 5
IE - Irlanda 4
ID - Indonesia 3
IN - India 3
JP - Giappone 2
ES - Italia 1
FR - Francia 1
NL - Olanda 1
PH - Filippine 1
Totale 730
Salva come PNG Salva come JPEG
Città #
Lawrence 51
Princeton 51
New York 48
Singapore 46
Shanghai 33
Moscow 30
Milan 20
Boardman 19
Helsinki 15
Ashburn 14
Busto Arsizio 6
Dublin 4
Lappeenranta 4
Monsummano Terme 4
Campodolcino 3
Gatchina 3
Perm 3
Rome 3
Seattle 3
St Petersburg 3
Dallas 2
Hanover 2
Huskvarna 2
Jakarta 2
Kuopio 2
Pune 2
Tokyo 2
Vaprio d'Adda 2
Vittoria 2
Voronezh 2
Andover 1
Banda Aceh 1
Bologna 1
Borås 1
Cernusco sul Naviglio 1
Cuneo 1
Falkenstein 1
Forlì 1
Littleton 1
Madrid 1
Mandaluyong 1
Naaldwijk 1
Nizhniy Novgorod 1
Paris 1
Pescara 1
Sacramento 1
San Francisco 1
Stockholm 1
Ternate 1
Verdellino 1
Viterbo 1
Washington 1
Yekaterinburg 1
Totale 406
Salva come PNG Salva come JPEG
Nome #
Failure of on-demand pre-exposure prophylaxis: the risk of HIV drug resistance 33
Viral bloodstream detection in mpox patients: An observational multicentric study 28
Publisher Correction: Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 (Scientific Reports, (2020), 10, 1, (21291), 10.1038/s41598-020-78039-1) 26
Dynamics of adaptive and innate immunity inpatients treated during primary human immunodeficiency virus infection: Results from Maraviroc in HIV Acute Infection (MAIN) randomized clinical trial 21
Prior Neisseria meningitidis (Nm) proctitis does not prevent Neisseria gonorrhoeae (Ng) proctitis among men who have sex with men (MSM) 19
48 week outcomes of maraviroc-containing regimens following the genotypic or Trofile assay in HIV-1 failing subjects: the OSCAR Study 19
Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients 19
Enhanced immunological recovery with early start of antiretroviral therapy during acute or early HIV infection–results of Italian network of acute HIV infection (Inaction) retrospective study 19
Activating Killer Immunoglobulin Receptors and HLA-C: A successful combination providing HIV-1 control 17
Pharmacokinetics of the raltegravir/maraviroc/etravirine combination 16
Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection 16
Beneficial effects of cART initiated during primary and chronic HIV-1 infection on immunoglobulin-expression of memory B-cell subsets 16
A new antigen scanning strategy for monitoring HIV-1 specific T-cell immune responses 16
Characteristics of HIV pre-exposure prophylaxis users at first PrEP counselling visit: the CSL-PrEP cohort 16
Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection-authors' response 15
Estimated glomerular filtration rate trajectories in HIV-infected subjects treated with different ritonavir-boosted protease inhibitors and tenofovir disoproxil fumarate or abacavir 15
Meningococcus B Vaccination Effectiveness Against Neisseria gonorrhoeae Infection in People Living With HIV: A Case-Control Study 15
Resistance to amprenavir before and after treatment with lopinavir/ritonavir in highly protease inhibitor-experienced HIV patients 14
An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project. 14
Antiretroviral therapy in geriatric HIV patients: The GEPPO cohort study 14
Late positivization of oropharyngeal, plasma, anal, semen, and urine specimens which tested negative at the time of mpox diagnosis 13
B-cell subset alterations and correlated factors in HIV-1 infection 13
Presence of multiple genotypes in subjects with HPV-16 infection is highly associated with anal squamous intraepithelial lesions in HIV-1 infected males 13
The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort 13
Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism 12
Durability of a novel salvage therapy in R5 HIV-infected patients: maraviroc, raltegravir, etravirine 12
Human Monkeypox Experience in a Tertiary Level Hospital in Milan, Italy, between May and October 2022: Epidemiological Features and Clinical Characteristics 11
Ageing with HIV: a multidisciplinary review 11
Detecting impaired glucose tolerance or type 2 diabetes mellitus by means of an oral glucose tolerance test in HIV-infected patients 11
Residual viremia in HIV-infected patients who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor based regimen 11
Viral Hepatitis and Human Papillomavirus Vaccination during HIV Pre-Exposure Prophylaxis: Factors Associated with Missed Vaccination 10
Complexity and Dynamics of HIV-1 Chemokine Receptor Usage in a Multidrug-Resistant Adolescent 10
Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapy 10
Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption 10
HIV-1-mediated insertional activation of STAT5B and BACH2 trigger viral reservoir in T regulatory cells 10
Four-year outcome of a PI and NRTI-sparing salvage regimen: maraviroc, raltegravir, etravirine 10
Soluble endothelial protein C receptor (sEPCR) as an inflammatory biomarker in naive HIV-infected patients during ART 10
Maraviroc 150mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN study 10
Human seminal plasma stimulates the migration of CD11c+ mononuclear phagocytes to the apical side of the colonic epithelium without altering the junctional complexes in an ex vivo human intestinal model 10
Increasing incidence and prevalence of metabolic syndrome in people living with HIV during the COVID-19 pandemic 9
High Propensity to Switch to Long-acting Injectable HIV PrEP with Cabotegravir in a Cohort of Oral PrEP Experienced Men who Have Sex with Men in Italy 9
Mpox Outbreak 2022: A Comparative Analysis of the Characteristics of Individuals Receiving MVA-BN Vaccination and People Diagnosed with Mpox Infection in Milan, Italy 9
Two individuals with potential monkeypox virus reinfection 9
Immune recovery and T cell subset analysis during effective treatment with maraviroc 9
Performance of commonly used genotypic assays and comparison with phenotypic assays of HIV-1 coreceptor tropism in acutely HIV-1-infected patients 9
Maraviroc in addition to cART during primary HIV infection: Results from MAIN randomized clinical trial and 96-weeks follow-up 9
Pustulosis acuta generalisata following chemotherapy in an HIV-positive patient 9
Durability and safety of a novel salvage therapy in R5-tropic HIV-infected patients: Maraviroc, raltegravir, etravirine 9
Influence of gender in predicting CCR5 coreceptor usage 9
HIV viral load monitoring during monkeypox virus infection among people with HIV 8
Immortal time bias: authors' reply 8
The Less Drugs Regimens (LDRs) therapy approach in HIV-1: an Italian expert panel perspective for the long-term management of HIV-1 infection. 8
Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection 8
A case of breakthrough mpox infection in an individual non-responder to MVA-BN vaccination 8
Prevalence and Risk Factors of Anal HPV Infection in MSM Living With HIV: Identifying the Target Groups to Prioritize for Immunization 8
Role of multi-site sampling in the diagnosis of human Monkeypox 7
Isolated monkeypox proctitis among men who have sex with men 7
Mpox in people with past infection or a complete vaccination course: a global case series 7
Rapid improvement of severe Mpox lesions with oral tecovirimat 7
HIV DNA loads, plasma residual viraemia and risk of virological rebound in heavily treated, virologically suppressed HIV-infected patients. 7
Viral tropism by geno2pheno as a tool for predicting CD4 decrease in HIV-1-infected naive patients with high CD4 counts 7
Etravirine plasma exposure is associated with virological efficacy in treatment-experienced HIV-positive patients 7
Long-term glucose tolerance in highly experienced HIV-infected patients receiving nucleoside analogue-sparing regimens 7
RPV plus DRV/cobi as 2DR option in HIV-infected subjects on virologic suppression 7
Breakthrough monkeypox infection among individuals previously immunized with smallpox or monkeypox vaccination 6
Persistent ocular mpox infection in an immunocompetent individual 6
Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience 6
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA Study Group 6
Levels of soluble endothelial protein C receptor are associated with CD4+ changes in Maraviroc-treated HIV-infected patients. 6
Is statin preventing cancer in HIV-1 infected individuals? An inappropriate methodology is a more likely explanation: authors' reply 6
Mpox Virus: Control of In-Hospital Occupational Transmission Experience from a Tertiary Level Hospital in Milan, Italy 5
Persistence of CCR5 usage among primary human immunodeficiency virus isolates of individuals receiving intermittent interleukin-2 5
Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group 5
Use of statins and risk of AIDS-defining and non-AIDS-defining malignancies among HIV-1 infected patients on antiretroviral therapy 5
Trends of Antimicrobial Susceptibility of Neisseria gonorrhoeae Isolates between 2012 and 2023: Results from an Open Italian Cohort 4
Totale 839
Salva come PNG Salva come JPEG
Categoria #
all - tutte 13.046
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.046
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20217 0 0 0 0 0 0 1 6 0 0 0 0
2021/202238 0 0 0 14 2 2 2 4 0 7 0 7
2022/2023280 114 66 14 2 1 30 12 30 5 2 1 3
2023/2024332 8 10 42 31 38 82 15 31 1 10 20 44
2024/2025142 130 12 0 0 0 0 0 0 0 0 0 0
Totale 839